艾米洛伊德静氨酸心肌病变的疾病修饰疗法:当前和新兴药物
Erika L Hellenbart1, Heather J Ipema1, Mary C Rodriguez-Ziccardi2
1Department of Pharmacy Practice, University of Illinois Chicago, Chicago, Illinois, USA.
Pharmacotherapy
|December 23, 2024
概括
新的药物显示出对治疗跨氨酸氨基粉症心肌病变性 (ATTR-CM) 的前景. 虽然已批准的治疗方法,如tafamidis和研究治疗方法提供希望,但高成本仍然是患者获得治疗的重要障碍.
科学领域:
- 心脏病学 心脏病学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 晶氨基粉症心肌病变 (ATTR-CM) 是一种由错误折叠的晶氨基蛋白引起的渐进性疾病.
- ATTR-CM导致粉样蛋白沉积在器官,特别是心脏,导致严重的后果.
- 最近的进展为ATTR-CM.引入了疾病修饰疗法.
研究的目的:
- 批判性地评估已批准和正在研究的ATTR-CM药物的临床试验数据.
- 总结一下当前关于治疗西氨化症心肌病的证据.
- 为了确定ATTR-CM治疗的未满足需求.
主要方法:
- 在PubMed和EMBASE数据库中进行全面的文献搜索.
- 包括公布到2024年8月的随机对照试验 (RCT).
- 叙事综述综合了关于ATTR-CM病理生理学,诊断和治疗疗效的数据.
主要成果:
- 胺稳定剂 (tafamidis,acoramidis) 和静音剂 (vutrisiran) 是有效的治疗方法.
- 新兴的治疗方法包括反感性寡核酸,基因编辑和单克隆抗体.
- 高昂的采购成本对成本效益和可访问性构成重大障碍.
结论:
- 已批准和正在研究的疾病修饰药物为ATTR-CM患者提供了重大希望.
- 可负担性和成本效益是广泛治疗的关键未满足需求.
- 需要继续进行研究和政策干预,以改善获得ATTR-CM疗法的机会.
相关概念视频
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
140
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140
01:26Heart Failure Drugs: Inotropic Agents
516
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516
01:28Drug Therapy
38
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
38
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444